indomethacin has been researched along with Cerebral Hemorrhage in 117 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prophylactic indomethacin reduces the risk of severe intraventricular hemorrhage (IVH) but does not reduce death or neurodevelopmental impairment (NDI) among extremely low birth weight (ELBW) infants." | 9.27 | Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage. ( Davis, PG; Foglia, EE; Haslam, R; Roberts, RS; Schmidt, B; Stoller, JZ, 2018) |
| "Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus." | 7.67 | Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. ( Bejar, R; Corazza, MS; Cvetnic, W; Davis, RF; Merritt, TA, 1984) |
| "Univariate analysis identified chorioamnionitis, treatment with surfactant, bronchopulmonary dysplasia, and abnormal cranial US findings as antecedents of CP." | 6.68 | Antecedents of cerebral palsy in a multicenter trial of indomethacin for intraventricular hemorrhage. ( Allan, WC; Katz, KH; Makuch, RW; Ment, LR; Vohr, B, 1997) |
| "Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios." | 5.38 | Indomethacin in pregnancy: applications and safety. ( Abou-Ghannam, G; Nassar, AH; Usta, IM, 2012) |
| "Prophylactic indomethacin reduces the risk of severe intraventricular hemorrhage (IVH) but does not reduce death or neurodevelopmental impairment (NDI) among extremely low birth weight (ELBW) infants." | 5.27 | Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage. ( Davis, PG; Foglia, EE; Haslam, R; Roberts, RS; Schmidt, B; Stoller, JZ, 2018) |
| "This historical cohort study included 45 infants born with birth weights of 1250 g or less and received indomethacin in the first 12 hours of life for intraventricular hemorrhage prevention." | 5.09 | The use of indomethacin for the prevention of intraventricular brain hemorrhage in high-risk neonates. ( Al-Alaiyan, SA; Al-Shawaf, EM; Aqeel, AY; Gamal, MH, 2000) |
| "The impact of early prophylactic use of intravenous indomethacin on the incidence and severity of periventricular-intraventricular hemorrhage and patent ductus arteriosus in 199 oxygen-requiring premature infants (less than or equal to 1300 g birth weight) was prospectively investigated." | 5.06 | Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. ( Bancalari, E; Bandstra, ES; Ferrer, PL; Flynn, J; Goldberg, RN; Gregorios, JB; Montalvo, BM; Pacheco, I, 1988) |
| "A high dose of oral ibuprofen was associated with a higher likelihood of hemodynamically significant PDA closure vs standard doses of intravenous ibuprofen or intravenous indomethacin; placebo or no treatment did not significantly change the likelihood of mortality, necrotizing enterocolitis, or intraventricular hemorrhage." | 4.98 | Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. ( Florez, ID; Mbuagbaw, L; Mitra, S; Sadeghirad, B; Tamayo, ME; Thabane, L; Vanniyasingam, T; Veroniki, AA; Zea, AM; Zhang, Y, 2018) |
| "Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users." | 4.93 | Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016) |
| " These factors (immaturity, hyperoxia, hypoxia, blood transfusions, intraventricular hemorrhage, apnea, infection, hypercarbia, hypocarbia, patent ductus arteriosus, prostaglandin synthetase inhibitors, vitamin E deficiency, lactic acidosis, prenatal complications, genetic factors) may all be present in an infant." | 4.76 | A reexamination of the role of oxygen in retrolental fibroplasia. ( Dangman, B; Lucey, JF, 1984) |
| " Magnesium sulfate administration, steroid administration, maternal diabetes mellitus, gestational age at delivery, indomethacin exposure, birthweight, and chorioamnionitis were all considered as possible covariates in the multivariable regression models." | 3.83 | Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. ( DeWitt, PE; Faucett, AM; Gibbs, RS; Metz, TD, 2016) |
| "The male C57BL/6 mice were divided into 4 groups of 10: sham, intracerebral hemorrhage (ICH), ICH + hirudin (thrombin inhibitor), and ICH + indometacin (Indo, an anti-inflammation drug)." | 3.81 | Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice. ( Jiang, C; Kang, X; Li, J; Wang, P; Yang, Y; Zhang, H; Zhang, M, 2015) |
| " Infants who had PDA and survived beyond 72 hours were included in multivariable logistic regression analyses that compared mortality or any severe neonatal morbidity (intraventricular hemorrhage grades ≥ 3, retinopathy of prematurity stages ≥ 3, bronchopulmonary dysplasia, or necrotizing enterocolitis stages ≥ 2) between treatment groups (conservative management, indomethacin only, surgical ligation only, or both indomethacin and ligation)." | 3.78 | Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. ( Allen, AC; Aziz, K; Lee, SK; Mirea, L; Ohlsson, A; Sankaran, K; Seshia, M; Shah, PS, 2012) |
| "Preterm infants with exposure to antenatal indomethacin might be at increased risk of grade I and II intraventricular haemorrhage and those with both ante- and postnatal exposure at an increased risk of necrotising enterocolitis and sepsis." | 3.70 | Perinatal indomethacin treatment and neonatal complications in preterm infants. ( Ikonen, S; Ojala, R; Tammela, O, 2000) |
| "Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus." | 3.67 | Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. ( Bejar, R; Corazza, MS; Cvetnic, W; Davis, RF; Merritt, TA, 1984) |
| " Intravenous indomethacin was administered to 67 infants with successful closure in 91% of the patients and in 83% of those with birth weights less than 1,000 g." | 3.66 | Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants. ( Alexson, CG; Harris, JP; Longfield, L; Manning, JA; Merritt, TA, 1982) |
| "Magnesium sulfate was administered intravenously with an 8 gm loading dose given over the first hour, 4 gm over the second hour, and then a maintenance infusion of 2." | 2.68 | Lack of effect of antenatal indomethacin on fetal cerebral blood flow. ( Clark, E; Cohen, LS; Parilla, BV; Tamura, RK, 1997) |
| "Univariate analysis identified chorioamnionitis, treatment with surfactant, bronchopulmonary dysplasia, and abnormal cranial US findings as antecedents of CP." | 2.68 | Antecedents of cerebral palsy in a multicenter trial of indomethacin for intraventricular hemorrhage. ( Allan, WC; Katz, KH; Makuch, RW; Ment, LR; Vohr, B, 1997) |
| "In addition, indomethacin closes the patent ductus arteriosus and is not associated with significant adverse drug events in very low birth weight neonates." | 2.67 | Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. ( Allan, W; Duncan, CC; Ehrenkranz, RA; Katz, KH; Ment, LR; Oh, W; Philip, AG; Scott, DT; Taylor, KJ; Vohr, B, 1994) |
| "Four indomethacin-treated and three saline solution-treated infants had parenchymal extension of the hemorrhage." | 2.67 | Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. ( Allan, W; Ehrenkranz, RA; Katz, KH; Makuch, RW; Ment, LR; Oh, W; Phillip, AG; Schneider, KC; Taylor, KJ; Vohr, B, 1994) |
| "Ibuprofen has less effect on blood flow velocity to important organs." | 2.66 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2020) |
| "The indomethacin-treated group had significant decreases in serum prostaglandin values 30 hours after the initiation of therapy." | 2.66 | Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants. ( Duncan, CC; Ehrenkranz, RA; Gettner, P; Kleinman, CS; Ment, LR; Pitt, BR; Scott, DT; Stewart, WB; Taylor, KJ, 1985) |
| "Of the infants who had a left-to-right patent ductus arteriosus shunt before treatment, 64% of the indomethacin-treated and 33% of the saline solution-treated infants no longer had a patent ductus arteriosus on day 5." | 2.66 | Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. ( Duncan, CC; Ehrenkranz, RA; Gettner, P; Kleinman, CS; Ment, LR; Scott, DT; Sherwonit, E; Taylor, KJ; Williams, J, 1988) |
| "Indomethacin has proven effective in closing the patent ductus arteriosus (PDA) in most low birth weight (LBW) neonates with this disorder." | 2.66 | Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. ( Ferguson, MG; Gibson, J; Joransen, JA; Reddy, NS; Rhodes, PG, 1988) |
| "Persistent patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants." | 2.46 | Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. ( Davis, PG; Fowlie, PW; McGuire, W, 2010) |
| "Indomethacin has been used successfully to treat symptomatic PDA and may also prevent or limit IVH in the neonatal period." | 2.41 | Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. ( Davis, PG; Fowlie, PW, 2002) |
| "Indomethacin is used to treat symptomatic patent ductus arteriosus and may prevent or limit intraventricular haemorrhage in the neonatal period." | 2.41 | Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. ( Fowlie, PW, 2000) |
| "The incidence of symptomatic patent ductus arteriosus is significantly reduced in treated infants, pooled estimate of risk difference -0." | 2.39 | Prophylactic indomethacin: systematic review and meta-analysis. ( Fowlie, PW, 1996) |
| "The aim of this study is to compare patent ductus arteriosus (PDA) management strategies and outcomes between the Neonatal Research Network of Japan (NRNJ) with proactive functional echocardiography and the Canadian Neonatal Network (CNN) with selective conventional echocardiography practice." | 1.42 | Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches. ( Fujimura, M; Isayama, T; Kusuda, S; Lee, SK; Mirea, L; Mori, R; Shah, PS, 2015) |
| "Indomethacin prophylaxis was given at <6 hours of life in 730 infants and at >6 hours of life to 168 infants." | 1.39 | Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration. ( Laptook, A; Mirza, H; Oh, W; Stonestreet, BS; Tucker, R; Vohr, B, 2013) |
| "Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios." | 1.38 | Indomethacin in pregnancy: applications and safety. ( Abou-Ghannam, G; Nassar, AH; Usta, IM, 2012) |
| "Indomethacin was not related to increased risk for periventricular-intraventricular hemorrhage or periventricular hemorrhagic infarction." | 1.33 | Indomethacin tocolysis and white matter injury in preterm infants. ( Flidel-Rimon, O; Friedman, S; Shinwell, ES; Steinberg, M, 2005) |
| "The indomethacin treatment cost was $95,157 and that of the control groups was $99,955." | 1.31 | Cost-effectiveness of prophylactic indomethacin in very-low-birth-weight infants. ( Goldberg, RN; Moya, MP, 2002) |
| "Persistent patent ductus arteriosus was more common in those infants delivered within 48 hours of maternal indomethacin exposure (40% versus 20% (p<0." | 1.30 | Antenatal indomethacin--adverse fetal effects confirmed. ( Baxendale, H; Harding, J; McCowan, L; McLeay, E; O'Donnell, C; Souter, D, 1998) |
| "The indomethacin-treated infants had a lower incidence of NEC and IVH." | 1.29 | Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight? ( Garcia-Prats, JA; Jaksic, T; Pokorny, WJ; Robie, DK; Waltrip, T, 1996) |
| "Antenatal indomethacin therapy for preterm labor appears to increase the risk of serious neonatal complications in infants born at or before 30 weeks' gestation." | 1.29 | Neonatal complications after the administration of indomethacin for preterm labor. ( Clyman, RI; Cooper, BA; Kuller, JA; Merrill, J; Norton, ME, 1993) |
| "Infants with a symptomatic patent ductus arteriosus had lower LTV than controls with the same severity of RDS." | 1.28 | The influence of respiratory distress syndrome on heart rate variability in very preterm infants. ( Hopman, JC; Kollée, LA; Stoelinga, GB; van Amen, JP; van Geijn, HP; van Ravenswaaij-Arts, CM, 1991) |
| "However, the incidence of periventricular leukomalacia was increased among infants exposed to any tocolytic agent; and cystic lesions occurred more commonly in those exposed to indomethacin." | 1.28 | Cerebral lesions in preterm infants after tocolytic indomethacin. ( Baerts, W; Fetter, WP; Hop, WC; Sauer, PJ; Spritzer, R; Wallenburg, HC, 1990) |
| "The effects of indomethacin on patent ductus arteriosus (PDA) were retrospectively studied by evaluating 1,600 consecutive infants less than 36 weeks gestation from 1983 to 1986." | 1.28 | The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus. ( Davis, JM; Hagberg, D; Hendricks-Munoz, KD; Manning, JA, 1990) |
| "Pretreatment with indomethacin produced a marked drop in the incidence of IVH as well as significant alterations in the blood pressure responses to the hemorrhagic hypotension/volume reexpansion insult." | 1.27 | Beagle puppy model of intraventricular hemorrhage. Effect of indomethacin on local cerebral glucose utilization. ( Duncan, CC; Lambrecht, R; Ment, LR; Scott, DT; Stewart, WB, 1984) |
| "Seventeen infants had a patent ductus arteriosus and were treated with indomethacin after the initial intracranial hemorrhage was diagnosed." | 1.27 | Does indomethacin cause extension of intracranial hemorrhages: a preliminary study. ( Ballard, R; Clyman, RI; Lane, B; Maher, P; Piecuch, R, 1985) |
| "This case reports heterotopic ossification which produced ankylosis around the hip joint in a young adult treated with steroids for moderate cognitive defects secondary to brain trauma." | 1.27 | Indomethacin: an adjunct to surgical excision of immature heterotopic bone formation in a patient with a severe head injury. A case report. ( Ritter, MA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (23.93) | 18.7374 |
| 1990's | 38 (32.48) | 18.2507 |
| 2000's | 22 (18.80) | 29.6817 |
| 2010's | 20 (17.09) | 24.3611 |
| 2020's | 9 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Kramer, KP | 1 |
| Minot, K | 1 |
| Butler, C | 1 |
| Haynes, K | 1 |
| Mason, A | 1 |
| Nguyen, L | 1 |
| Wynn, S | 1 |
| Liebowitz, M | 1 |
| Rogers, EE | 1 |
| Miller, CJ | 1 |
| Prusakov, P | 1 |
| Magers, J | 1 |
| Speaks, S | 1 |
| Sacic, H | 1 |
| Escobar, K | 1 |
| Abdel-Rasoul, M | 1 |
| Nelin, LD | 1 |
| Shukla, VV | 1 |
| Klinger, A | 1 |
| Yazdi, S | 1 |
| Rahman, AKMF | 1 |
| Wright, S | 1 |
| Barganier, A | 1 |
| Ambalavanan, N | 1 |
| Carlo, WA | 1 |
| Ramani, M | 1 |
| Yao, SL | 1 |
| Smit, E | 1 |
| Odd, D | 1 |
| Saxton, SN | 1 |
| Evered, J | 1 |
| McCoy, K | 1 |
| Atkins, K | 1 |
| Mitra, S | 2 |
| Hatfield, T | 1 |
| Campbell-Yeo, M | 1 |
| Dorling, J | 1 |
| Johnston, BC | 1 |
| Razak, A | 1 |
| Patel, W | 1 |
| Durrani, NUR | 1 |
| Pullattayil, AK | 1 |
| Hanke, K | 1 |
| Fortmann, I | 1 |
| Humberg, A | 1 |
| Faust, K | 1 |
| Kribs, A | 1 |
| Prager, S | 1 |
| Felderhoff-Müser, U | 1 |
| Krüger, M | 1 |
| Heckmann, M | 1 |
| Jäger, A | 1 |
| Andres, O | 1 |
| Spiegler, J | 1 |
| Härtel, C | 1 |
| Herting, E | 1 |
| Göpel, W | 1 |
| Bhat, R | 1 |
| Zayek, M | 1 |
| Maertens, P | 1 |
| Eyal, F | 1 |
| Ohlsson, A | 2 |
| Shah, SS | 1 |
| Foglia, EE | 1 |
| Roberts, RS | 1 |
| Stoller, JZ | 1 |
| Davis, PG | 4 |
| Haslam, R | 1 |
| Schmidt, B | 1 |
| Florez, ID | 1 |
| Tamayo, ME | 1 |
| Mbuagbaw, L | 1 |
| Vanniyasingam, T | 1 |
| Veroniki, AA | 1 |
| Zea, AM | 1 |
| Zhang, Y | 1 |
| Sadeghirad, B | 1 |
| Thabane, L | 1 |
| Mondal, T | 1 |
| Chaudhuri, D | 1 |
| Li, B | 1 |
| Shivananda, S | 1 |
| Dutta, S | 1 |
| Mirza, H | 2 |
| Oh, W | 10 |
| Laptook, A | 1 |
| Vohr, B | 10 |
| Tucker, R | 2 |
| Stonestreet, BS | 3 |
| Singh, R | 2 |
| Gorstein, SV | 1 |
| Bednarek, F | 1 |
| Chou, JH | 1 |
| McGowan, EC | 1 |
| Visintainer, PF | 2 |
| Luque, MJ | 1 |
| Tapia, JL | 1 |
| Villarroel, L | 1 |
| Marshall, G | 1 |
| Musante, G | 1 |
| Carlo, W | 1 |
| Kattan, J | 1 |
| Isayama, T | 1 |
| Mirea, L | 2 |
| Mori, R | 1 |
| Kusuda, S | 1 |
| Fujimura, M | 1 |
| Lee, SK | 2 |
| Shah, PS | 2 |
| Yang, Y | 1 |
| Zhang, M | 1 |
| Kang, X | 1 |
| Jiang, C | 1 |
| Zhang, H | 1 |
| Wang, P | 1 |
| Li, J | 1 |
| Faucett, AM | 1 |
| Metz, TD | 1 |
| DeWitt, PE | 1 |
| Gibbs, RS | 1 |
| Ungprasert, P | 1 |
| Matteson, EL | 1 |
| Thongprayoon, C | 1 |
| Laptook, AR | 1 |
| Vohr, BR | 4 |
| Stoll, BJ | 1 |
| Kandefer, S | 1 |
| Tofé Valera, I | 1 |
| Jaraba Caballero, MP | 1 |
| Ruiz González, MD | 1 |
| Rodríguez Benítez, MV | 1 |
| Parraga Quiles, MJ | 1 |
| Kalani, M | 1 |
| Shariat, M | 1 |
| Khalesi, N | 1 |
| Farahani, Z | 1 |
| Ahmadi, S | 1 |
| McCrea, HJ | 1 |
| Ment, LR | 25 |
| Luu, TM | 1 |
| Schneider, KC | 9 |
| Katz, KH | 12 |
| Allan, WC | 8 |
| Sharma, R | 1 |
| Hudak, ML | 1 |
| Tepas, JJ | 1 |
| Wludyka, PS | 1 |
| Teng, RJ | 1 |
| Hastings, LK | 1 |
| Renfro, WH | 1 |
| Marvin, WJ | 1 |
| Fowlie, PW | 6 |
| McGuire, W | 2 |
| Abou-Ghannam, G | 1 |
| Usta, IM | 1 |
| Nassar, AH | 1 |
| Maruyama, K | 1 |
| Fujiu, T | 1 |
| Sankaran, K | 1 |
| Seshia, M | 1 |
| Allen, AC | 1 |
| Aziz, K | 1 |
| Allan, W | 4 |
| Westerveld, M | 6 |
| Duncan, CC | 13 |
| Makuch, RW | 11 |
| Osborn, DA | 1 |
| Evans, N | 1 |
| Kluckow, M | 1 |
| Ehrenkranz, R | 1 |
| Philip, AG | 4 |
| Scott, DT | 9 |
| Imberti, R | 1 |
| Fuardo, M | 1 |
| Bellinzona, G | 1 |
| Pagani, M | 1 |
| Langer, M | 1 |
| Friedman, S | 1 |
| Flidel-Rimon, O | 1 |
| Steinberg, M | 1 |
| Shinwell, ES | 1 |
| Slŭncheva, B | 1 |
| Vakrilova, L | 1 |
| Emilova, Z | 1 |
| Kalaĭdzhieva, M | 1 |
| Garnizov, T | 1 |
| Cordero, L | 1 |
| Nankervis, CA | 1 |
| Delooze, D | 1 |
| Giannone, PJ | 1 |
| Al-Amro, SA | 1 |
| Al-Kharfi, TM | 1 |
| Thabit, AA | 1 |
| Al-Mofada, SM | 1 |
| Kesler, SR | 1 |
| Reiss, AL | 1 |
| Watson, C | 1 |
| Maller-Kesselman, J | 1 |
| Silbereis, J | 1 |
| Constable, RT | 1 |
| Brooks, DP | 1 |
| Share, L | 1 |
| Crofton, JT | 1 |
| Nasjletti, A | 1 |
| Lucey, JF | 1 |
| Dangman, B | 1 |
| Stewart, WB | 5 |
| Lambrecht, R | 2 |
| Corazza, MS | 1 |
| Davis, RF | 1 |
| Merritt, TA | 2 |
| Bejar, R | 1 |
| Cvetnic, W | 1 |
| Harris, JP | 1 |
| Alexson, CG | 1 |
| Longfield, L | 1 |
| Manning, JA | 2 |
| Wells, JT | 1 |
| Ehrenkranz, RA | 9 |
| Taylor, KJ | 5 |
| Volpe, JJ | 3 |
| Reynolds, EO | 1 |
| Meek, J | 1 |
| Phillip, AG | 1 |
| Norton, ME | 1 |
| Merrill, J | 1 |
| Cooper, BA | 1 |
| Kuller, JA | 1 |
| Clyman, RI | 3 |
| van Bel, F | 1 |
| Klautz, RJ | 1 |
| Steendijk, P | 1 |
| Schipper, IB | 1 |
| Teitel, DF | 1 |
| Baan, J | 1 |
| Schneider, K | 1 |
| Sandler, RS | 1 |
| Robie, DK | 1 |
| Waltrip, T | 1 |
| Garcia-Prats, JA | 1 |
| Pokorny, WJ | 1 |
| Jaksic, T | 1 |
| Iannucci, TA | 1 |
| Besinger, RE | 1 |
| Fisher, SG | 1 |
| Gianopoulos, JG | 1 |
| Tomich, PG | 1 |
| Bada, HS | 2 |
| Weeks, JW | 1 |
| Mailhes, JB | 1 |
| Lewis, DF | 1 |
| Parilla, BV | 1 |
| Tamura, RK | 1 |
| Cohen, LS | 1 |
| Clark, E | 1 |
| Chugh, K | 1 |
| Macones, GA | 1 |
| Robinson, CA | 1 |
| Blair, E | 1 |
| Yanowitz, TD | 1 |
| Yao, AC | 1 |
| Werner, JC | 1 |
| Pettigrew, KD | 1 |
| Souter, D | 1 |
| Harding, J | 1 |
| McCowan, L | 1 |
| O'Donnell, C | 1 |
| McLeay, E | 1 |
| Baxendale, H | 1 |
| Makuch, R | 1 |
| Humphrey, M | 1 |
| King, G | 1 |
| Hill, A | 1 |
| Narayanan, M | 1 |
| Schlueter, M | 1 |
| Ojala, R | 1 |
| Ikonen, S | 1 |
| Tammela, O | 1 |
| Sparrow, SS | 1 |
| Cotton, RB | 1 |
| Rosen, LJ | 1 |
| Zucker, D | 1 |
| Oppenheimer-Gazit, V | 1 |
| Yagel, S | 1 |
| Al-Shawaf, EM | 1 |
| Al-Alaiyan, SA | 1 |
| Aqeel, AY | 1 |
| Gamal, MH | 1 |
| Moya, MP | 1 |
| Goldberg, RN | 2 |
| Morales-Suárez, M | 1 |
| Lemus-Varela, L | 1 |
| Udaeta-Mora, E | 1 |
| Cardiel-Marmolejo, L | 1 |
| Rodríguez-Balderrama, I | 1 |
| Liz-Cedillo, RE | 1 |
| Ardito, TA | 1 |
| Huang, E | 1 |
| Madri, JA | 1 |
| van Ravenswaaij-Arts, CM | 1 |
| Hopman, JC | 1 |
| Kollée, LA | 1 |
| van Amen, JP | 1 |
| Stoelinga, GB | 1 |
| van Geijn, HP | 1 |
| Lamp, KC | 1 |
| Reynolds, MS | 1 |
| Gal, P | 1 |
| James, C | 1 |
| Reed, MD | 1 |
| Morales, WJ | 1 |
| Padmini, P | 1 |
| Shenoi, A | 1 |
| Narang, A | 1 |
| Bhakoo, ON | 1 |
| Baerts, W | 1 |
| Fetter, WP | 1 |
| Hop, WC | 1 |
| Wallenburg, HC | 1 |
| Spritzer, R | 1 |
| Sauer, PJ | 1 |
| Davis, JM | 1 |
| Hendricks-Munoz, KD | 1 |
| Hagberg, D | 1 |
| Green, RS | 1 |
| Pourcyrous, M | 1 |
| Leffler, CW | 1 |
| Korones, SB | 1 |
| Magill, HL | 1 |
| Arheart, K | 1 |
| Fitch, CW | 1 |
| Anderson, GD | 1 |
| Somes, G | 1 |
| Ritter, MA | 1 |
| Bandstra, ES | 1 |
| Montalvo, BM | 1 |
| Pacheco, I | 1 |
| Ferrer, PL | 1 |
| Flynn, J | 1 |
| Gregorios, JB | 1 |
| Bancalari, E | 1 |
| Chemtob, S | 1 |
| Laudignon, N | 1 |
| Aranda, JV | 1 |
| Perlman, JM | 1 |
| Hanigan, WC | 1 |
| Kennedy, G | 1 |
| Roemisch, F | 1 |
| Anderson, R | 1 |
| Cusack, T | 1 |
| Powers, W | 1 |
| Kleinman, CS | 2 |
| Gettner, P | 2 |
| Sherwonit, E | 1 |
| Williams, J | 1 |
| Rhodes, PG | 1 |
| Ferguson, MG | 1 |
| Reddy, NS | 1 |
| Joransen, JA | 1 |
| Gibson, J | 1 |
| Kauffman, RE | 1 |
| Barrington, KJ | 1 |
| Finer, NN | 1 |
| Szymonowicz, W | 1 |
| Yu, VY | 1 |
| Kühl, PG | 1 |
| Schweer, H | 1 |
| Seyberth, HW | 1 |
| Maher, P | 1 |
| Lane, B | 1 |
| Ballard, R | 1 |
| Piecuch, R | 1 |
| Pitt, BR | 1 |
| Bavazzano, A | 3 |
| Fanciullacci, M | 3 |
| Franchi, G | 3 |
| Sicuteri, F | 2 |
| Siguteri, F | 1 |
| Del Bianco, PL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dynamic Prediction of Bleeding in Thrombocytopenic Preterm Neonates[NCT06043050] | 1,200 participants (Anticipated) | Observational | 2022-09-26 | Recruiting | |||
| Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial[NCT00033917] | Phase 3 | 630 participants (Actual) | Interventional | 1989-09-30 | Completed | ||
| Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)[NCT06064825] | 500 participants (Anticipated) | Observational | 2023-11-30 | Not yet recruiting | |||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage[NCT00665769] | 103 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Recruitment was proceeding too slowly) | |||
| High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study[NCT00589953] | Phase 2 | 22 participants (Actual) | Interventional | 2007-07-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age (NCT00033917)
Timeframe: at 5 days
| Intervention | IVH (Number) |
|---|---|
| Indomethacin | 25 |
| Placebo | 40 |
"Peabody Picture Vocabulary Test (PPVT) This is a semantic language test. The mean value is 100; standard deviation is 16 points. A higher score means better language; a lower score means poorer language.~There are no subscales to the PPVT. The measurement unit is points on a scale. A score < 70 indicates severely abnormal language function." (NCT00033917)
Timeframe: at 8 years
| Intervention | participants with PPVT score < 70 (Number) |
|---|---|
| Indomethacin - no IVH | 12 |
| Indomethacin - IVH | 5 |
| Placebo - no IVH | 24 |
| Placebo - IVH | 7 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
25 reviews available for indomethacin and Cerebral Hemorrhage
| Article | Year |
|---|---|
The effectiveness of interventions to prevent intraventricular haemorrhage in premature infants: A systematic review and network meta-analysis.
Topics: Cerebral Hemorrhage; Humans; Indomethacin; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant | 2023 |
Interventions to Reduce Severe Brain Injury Risk in Preterm Neonates: A Systematic Review and Meta-analysis.
Topics: Adrenal Cortex Hormones; Brain Injuries; Cerebral Hemorrhage; Ethamsylate; Female; Humans; Indometha | 2023 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duc | 2020 |
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Bayes Theorem; Cerebral Hemorrhage | 2018 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof | 2016 |
The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Coagulants; Cyclooxygenase Inhibitors; Factor VIIa; Humans | 2008 |
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2010 |
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2002 |
Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Humans; Indomethacin; Infant, Newborn; | 2003 |
A reexamination of the role of oxygen in retrolental fibroplasia.
Topics: Anencephaly; Apnea; Carbon Dioxide; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Exchange Transfu | 1984 |
Prevention of intraventricular hemorrhage in preterm infants.
Topics: Adrenal Cortex Hormones; Cerebral Hemorrhage; Delivery, Obstetric; Female; Humans; Indomethacin; Inf | 1995 |
Prophylactic indomethacin: systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Ind | 1996 |
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-S | 1996 |
Routine indomethacin prophylaxis: has the time come?
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Humans; Indomethacin; Infant, Newborn; Infant, Prema | 1996 |
Intraventricular hemorrhage: emphasis on prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Blood Coagulation Disorders; Cereb | 1998 |
Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2000 |
The great tocolytic debate: some pitfalls in the study of safety.
Topics: Cerebral Hemorrhage; Female; Humans; Indomethacin; MEDLINE; Obstetric Labor, Premature; Pregnancy; R | 2001 |
Indomethacin for prevention of neonatal intraventricular hemorrhage.
Topics: Birth Weight; Cerebral Hemorrhage; Cerebral Ventricles; Female; Humans; Indomethacin; Infant, Newbor | 1991 |
Antenatal therapy to minimize neonatal intraventricular hemorrhage.
Topics: Cerebral Hemorrhage; Female; Humans; Indomethacin; Infant, Newborn; Phenobarbital; Pregnancy; Prenat | 1991 |
Intraventricular hemorrhage of the preterm neonate: prevention studies.
Topics: Animals; Cerebral Hemorrhage; Cerebral Ventricles; Clinical Trials as Topic; Ethamsylate; Humans; In | 1988 |
Intraventricular hemorrhage in the premature infant--current concepts. Part II.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Combined Modality Therapy; Echoencephalography; Ethamsylat | 1989 |
Intraventricular hemorrhage of the preterm neonate: prevention studies.
Topics: Animals; Benzenesulfonates; Brain; Cerebral Hemorrhage; Cerebrovascular Circulation; Clinical Trials | 1988 |
Drug therapy in hypoxic-ischemic cerebral insults and intraventricular hemorrhage of the newborn.
Topics: Asphyxia Neonatorum; Barbiturates; Brain Ischemia; Cerebral Hemorrhage; Female; Fetal Hypoxia; Human | 1987 |
Prevention of neonatal intraventricular hemorrhage.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Cerebrovascular Circulation; Ethamsylate; Humans; Indometh | 1987 |
Therapeutic interventions to prevent intracerebral hemorrhage in preterm infants.
Topics: Cerebral Hemorrhage; Cerebrovascular Circulation; Clinical Trials as Topic; Ethamsylate; Humans; Ind | 1986 |
32 trials available for indomethacin and Cerebral Hemorrhage
| Article | Year |
|---|---|
Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage.
Topics: Birth Weight; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug Administration Schedule; Female; | 2018 |
A Comparison of Early Ibuprofen and Indomethacin Administration to Prevent Intraventricular Hemorrhage Among Preterm Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Ductus Arte | 2016 |
Trajectories of receptive language development from 3 to 12 years of age for very preterm children.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cerebral Hemorrhage; Child; Child, P | 2009 |
Effects of prophylactic indomethacin on renal and intestinal blood flows in premature infants.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infan | 2012 |
School-age outcomes of very low birth weight infants in the indomethacin intraventricular hemorrhage prevention trial.
Topics: Cerebral Hemorrhage; Cerebral Palsy; Cerebral Ventricles; Child; Cohort Studies; Developmental Disab | 2003 |
Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebrovascular Circulation; Cross-Ove | 2003 |
Prevention of intraventricular hemorrhage by indomethacin in male preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Child; Child, Preschool; Female; Humans; Incidence; Indo | 2004 |
[Prevention of brain hemorrhage in infants with low and extremely low birth weight and infants treated with surfactants. Late observation].
Topics: Cerebral Hemorrhage; Cerebrovascular Circulation; Drug Therapy, Combination; Humans; Indomethacin; I | 2006 |
Brain volume reductions within multiple cognitive systems in male preterm children at age twelve.
Topics: Birth Weight; Brain; Case-Control Studies; Cerebral Hemorrhage; Child; Cognition Disorders; Female; | 2008 |
Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants.
Topics: Cerebral Hemorrhage; Cesarean Section; Female; Humans; Indomethacin; Infant, Low Birth Weight; Infan | 1995 |
Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weig | 1994 |
Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial.
Topics: Cerebral Hemorrhage; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; Indome | 1994 |
Risk period for intraventricular hemorrhage of the preterm neonate is independent of gestational age.
Topics: Age of Onset; Cerebral Hemorrhage; Cerebral Ventricles; Gestational Age; Humans; Indomethacin; Infan | 1993 |
Antenatal exposure to steroids and the additional prophylaxis effect of indomethacin to prevent intraventricular hemorrhage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Embryonic and Fetal Development; Femal | 1996 |
Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial.
Topics: Cerebral Hemorrhage; Chi-Square Distribution; Child Development; Child, Preschool; Cyclooxygenase In | 1996 |
Antecedents of cerebral palsy in a multicenter trial of indomethacin for intraventricular hemorrhage.
Topics: Cerebral Hemorrhage; Cerebral Palsy; Cerebral Ventricles; Chorioamnionitis; Female; Gestational Age; | 1997 |
Lack of effect of antenatal indomethacin on fetal cerebral blood flow.
Topics: Adolescent; Adult; Brain; Cerebral Hemorrhage; Female; Fetus; Humans; Incidence; Indomethacin; Infus | 1997 |
Neurodevelopmental outcome with early indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Humans; Indomethacin; Infant, Newborn; | 1997 |
Cognitive outcome at 4 1/2 years of very low birth weight infants enrolled in the multicenter indomethacin intraventricular hemorrhage prevention trial.
Topics: Brain Damage, Chronic; Cerebral Hemorrhage; Cerebral Ventricles; Child, Preschool; Cyclooxygenase In | 1998 |
Early-onset intraventricular hemorrhage in preterm neonates: incidence of neurodevelopmental handicap.
Topics: Aging; Brain Diseases; Cerebral Hemorrhage; Cerebral Palsy; Humans; Indomethacin; Infant, Newborn; I | 1999 |
Outcome of children in the indomethacin intraventricular hemorrhage prevention trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cerebral Hemorrhage; Cerebral Ventri | 2000 |
The use of indomethacin for the prevention of intraventricular brain hemorrhage in high-risk neonates.
Topics: Birth Weight; Cerebral Hemorrhage; Cerebral Ventricles; Cohort Studies; Gestational Age; Humans; Inc | 2000 |
[Indomethacin in the prevention of subependymal-intraventricular hemorrhage in preterm newborns with conventional mechanical ventilation].
Topics: Cerebral Hemorrhage; Double-Blind Method; Ependyma; Humans; Indomethacin; Infant, Newborn; Infant, P | 1992 |
Indomethacin reduces the risks of severe intraventricular hemorrhage.
Topics: Apgar Score; Birth Weight; Cerebral Hemorrhage; Clinical Trials as Topic; Double-Blind Method; Femal | 1989 |
Intraventricular hemorrhage of the preterm neonate: prevention studies.
Topics: Animals; Benzenesulfonates; Brain; Cerebral Hemorrhage; Cerebrovascular Circulation; Clinical Trials | 1988 |
Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants.
Topics: Birth Weight; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, | 1988 |
Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates.
Topics: Birth Weight; Cerebral Hemorrhage; Double-Blind Method; Female; Humans; Indomethacin; Infant, Newbor | 1988 |
Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weig | 1988 |
Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus.
Topics: Cerebral Hemorrhage; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; Indome | 1988 |
Therapeutic interventions to prevent intracerebral hemorrhage in preterm infants.
Topics: Cerebral Hemorrhage; Cerebrovascular Circulation; Clinical Trials as Topic; Ethamsylate; Humans; Ind | 1986 |
Indomethacin for prevention of intraventricular hemorrhage.
Topics: Cerebral Hemorrhage; Clinical Trials as Topic; Humans; Indomethacin; Infant, Low Birth Weight; Infan | 1986 |
Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants.
Topics: 6-Ketoprostaglandin F1 alpha; Cerebral Hemorrhage; Clinical Trials as Topic; Ductus Arteriosus, Pate | 1985 |
62 other studies available for indomethacin and Cerebral Hemorrhage
| Article | Year |
|---|---|
Reduction of Severe Intraventricular Hemorrhage in Preterm Infants: A Quality Improvement Project.
Topics: Betamethasone; Cerebral Hemorrhage; Child; Female; Humans; Indomethacin; Infant; Infant, Extremely P | 2022 |
Effects of prophylactic indomethacin on intraventricular hemorrhage and adverse outcomes in neonatal intensive care unit.
Topics: Cerebral Hemorrhage; Child; Gestational Age; Humans; Indomethacin; Infant; Infant, Extremely Prematu | 2022 |
Prevention of severe brain injury in very preterm neonates: A quality improvement initiative.
Topics: Bicarbonates; Brain Injuries; Cerebral Hemorrhage; Humans; Indomethacin; Infant; Infant, Extremely P | 2022 |
Effects of a small-baby protocol on early and long-term outcomes in extremely preterm infants: A quality improvement study.
Topics: Cerebral Hemorrhage; Female; Humans; Indomethacin; Infant; Infant, Extremely Premature; Infant, Newb | 2023 |
Evaluation of Health-Related Values and Preferences of Adults Who Were Preterm Infants and Parents of Preterm Infants Concerning Use of Prophylactic Cyclooxygenase Inhibitor Drugs.
Topics: Acetaminophen; Adult; Cerebral Hemorrhage; Child; Cross-Sectional Studies; Cyclooxygenase Inhibitors | 2023 |
Indomethacin Prophylaxis Is Associated with Reduced Risk of Intraventricular Hemorrhage in Extremely Preterm Infants Born in the Context of Amniotic Infection Syndrome.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; Infant, Extrem | 2023 |
A single-dose indomethacin prophylaxis for reducing perinatal brain injury in extremely low birth weight infants: a non-inferiority analysis.
Topics: Alabama; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Drug Administration Schedule; | 2019 |
Prophylactic indomethacin worsens short-term respiratory outcomes in extremely low-birth-weight infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Continuous Positive Airway Pressure; Ductus Arteriosus, | 2014 |
Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug Administration Schedule; Female; Follow-Up Stud | 2013 |
A predictive model for SIVH risk in preterm infants and targeted indomethacin therapy for prevention.
Topics: Cerebral Hemorrhage; Child; Child, Preschool; Female; Humans; Indomethacin; Infant; Infant, Newborn; | 2013 |
A risk prediction model for severe intraventricular hemorrhage in very low birth weight infants and the effect of prophylactic indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Female; Humans; Incidence; Indomethaci | 2014 |
Predictive models for severe intraventricular hemorrhage in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Female; Humans; Indomethacin; Infant, | 2014 |
Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches.
Topics: Bronchopulmonary Dysplasia; Canada; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Duc | 2015 |
Thrombin-induced microglial activation impairs hippocampal neurogenesis and spatial memory ability in mice.
Topics: Animals; Cell Proliferation; Cerebral Hemorrhage; Corpus Striatum; Dentate Gyrus; Doublecortin Prote | 2015 |
Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Birth Weight; Case-Control Studies; Cerebral Hemorrhage; | 2016 |
Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Drug Administration Schedule; Ductus A | 2016 |
The Role of Paracetamol for Closing Patent Ductus Arteriosus. A Challenging Alternative for Ductal Closure?
Topics: Acetaminophen; Administration, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorr | 2016 |
Prenatal or postnatal indomethacin exposure and neonatal gut injury associated with isolated intestinal perforation and necrotizing enterocolitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Drug Administrati | 2010 |
Indomethacin in pregnancy: applications and safety.
Topics: Cerclage, Cervical; Cerebral Hemorrhage; Ductus Arteriosus; Enterocolitis, Necrotizing; Female; Fetu | 2012 |
Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Ductus Arte | 2012 |
Change in cognitive function over time in very low-birth-weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cerebral Hemorrhage; Child; Child, P | 2003 |
The use of indomethacin in the treatment of plateau waves: effects on cerebral perfusion and oxygenation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Volume; Brain; Brain Injuries; Carbon Dioxide; Cerebr | 2005 |
Indomethacin tocolysis and white matter injury in preterm infants.
Topics: Cerebral Hemorrhage; Female; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Premature; Israe | 2005 |
Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?
Topics: Cerebral Hemorrhage; Comorbidity; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, N | 2007 |
Risk factors for acute retinopathy of prematurity.
Topics: Birth Weight; Cerebral Hemorrhage; Female; Gestational Age; Humans; Incidence; Indomethacin; Infant, | 2007 |
Central indomethacin enhances volume-dependent vasopressin release.
Topics: Animals; Blood Pressure; Cerebral Hemorrhage; Cisterna Magna; Dogs; Heart Rate; Indomethacin; Inject | 1984 |
Beagle puppy model of intraventricular hemorrhage: randomized indomethacin prevention trial.
Topics: Animals; Animals, Newborn; Blood Pressure; Cerebral Hemorrhage; Cerebral Ventricles; Cerebrovascular | 1983 |
Beagle puppy model of intraventricular hemorrhage. Effect of indomethacin on local cerebral glucose utilization.
Topics: Animals; Animals, Newborn; Brain; Cerebral Hemorrhage; Dogs; Glucose; Indomethacin; Models, Biologic | 1984 |
Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus.
Topics: Bleeding Time; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Hemorrhage; Humans; Indometha | 1984 |
Beagle puppy model of intraventricular hemorrhage. Effect of indomethacin on cerebral blood flow.
Topics: Animals; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular Circulation; Disease Models, Animal; D | 1983 |
Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants.
Topics: Age Factors; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Paten | 1982 |
Brain injury caused by intraventricular hemorrhage: is indomethacin the silver bullet for prevention?
Topics: Cerebral Hemorrhage; Cerebral Infarction; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Ne | 1994 |
Prevention of periventricular hemorrhage.
Topics: Cerebral Hemorrhage; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 1994 |
Neonatal complications after the administration of indomethacin for preterm labor.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Female; Fetus; Huma | 1993 |
The influence of indomethacin on the autoregulatory ability of the cerebral vascular bed in the newborn lamb.
Topics: Animals; Animals, Newborn; Blood Flow Velocity; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular | 1993 |
Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight?
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cerebral Ventricles; Chemotherapy, Adjuvant; Cycloo | 1996 |
Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Drug Therapy, Combination; Female; Humans; Incidence; Indo | 1996 |
Antenatal indomethacin exposure and neonatal intraventricular hemorrhage: a side effect or an association?
Topics: Cerebral Hemorrhage; Female; Humans; Indomethacin; Infant, Newborn; Maternal-Fetal Exchange; Pregnan | 1997 |
Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits.
Topics: Cerebral Hemorrhage; Decision Support Techniques; Enterocolitis, Pseudomembranous; Female; Gestation | 1997 |
Antecedents of cerebral palsy in a multicenter trial of indomethacin for intraventricular hemorrhage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Palsy; Humans; Indomethacin; | 1997 |
Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants.
Topics: Analysis of Variance; Blood Flow Velocity; Cerebral Hemorrhage; Cerebrovascular Circulation; Cycloox | 1998 |
Antenatal indomethacin--adverse fetal effects confirmed.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Infant | 1998 |
Re: The debate regarding the risks of tocolytic agents.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Kidney | 1998 |
Incidence and outcome of a 10-fold indomethacin overdose in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Art | 1999 |
Perinatal indomethacin treatment and neonatal complications in preterm infants.
Topics: Cerebral Hemorrhage; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infa | 2000 |
Don't discard your indomethacin yet.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Brain; Cerebral Hemorrhage; Clinical Trials a | 2000 |
Treating extremely low birthweight infants with prophylactic indomethacin. Evidence for short term benefits only.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arterios | 2002 |
Cost-effectiveness of prophylactic indomethacin in very-low-birth-weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cohort Studies; Cost-Benefit Analysis; | 2002 |
Indomethacin promotes germinal matrix microvessel maturation in the newborn beagle pup.
Topics: Animals; Animals, Newborn; Brain; Cerebral Hemorrhage; Cerebral Ventricles; Collagen; Dogs; Germ Lay | 1992 |
The influence of respiratory distress syndrome on heart rate variability in very preterm infants.
Topics: Age Factors; Birth Weight; Blood Gas Monitoring, Transcutaneous; Cerebral Hemorrhage; Ductus Arterio | 1991 |
Indomethacin therapy for intraventricular hemorrhage in neonates: another use for that "old" drug.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Humans; Indomethacin; Infant, Newborn; Infant, Premature; | 1991 |
Indomethacin therapy in the newborn.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Drug Interactions; Ductus Arteriosus, Patent; Humans; Indo | 1991 |
Cerebral lesions in preterm infants after tocolytic indomethacin.
Topics: Administration, Rectal; Brain; Brain Damage, Chronic; Cerebral Hemorrhage; Dose-Response Relationshi | 1990 |
The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus.
Topics: Acute Kidney Injury; Cerebral Hemorrhage; Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indome | 1990 |
Prophylactic agents in the prevention of periventricular hemorrhage.
Topics: Brain Damage, Chronic; Cerebral Hemorrhage; Humans; Indomethacin; Infant, Newborn | 1989 |
Indomethacin: an adjunct to surgical excision of immature heterotopic bone formation in a patient with a severe head injury. A case report.
Topics: Adult; Bone and Bones; Cerebral Hemorrhage; Choristoma; Hip Dislocation; Humans; Indomethacin; Male; | 1987 |
Periventricular haemorrhage: association with patent ductus arteriosus and its treatment with indomethacin or surgery.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, N | 1987 |
Indomethacin for prevention of intraventricular hemorrhage in low birth weight infants.
Topics: Cerebral Hemorrhage; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Prostaglandins | 1986 |
Does indomethacin cause extension of intracranial hemorrhages: a preliminary study.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infan | 1985 |
[Experimental intracranial hemorrhage. Protective action of drugs with anti-protease activity].
Topics: Aminocaproates; Animals; Aprotinin; Cerebral Hemorrhage; Chymotrypsin; Cortisone; Guinea Pigs; Hista | 1969 |
[Influence of a kallikrein inhibitor on the phenomenology of experimental intracranial hemorrhage].
Topics: Aminocaproates; Animals; Aprotinin; Cerebral Hemorrhage; Chymotrypsin; Cortisone; Heparin; Indometha | 1967 |
Kinins and intracranial hemorrhages.
Topics: Animals; Brain; Capillaries; Cerebral Hemorrhage; Escape Reaction; Humans; Indomethacin; Injections, | 1970 |